StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

17-Hydroxy-6-methylpregna-4,6-dien-3,20-dion-17-acetat

Megestrol Acetate

HCID 11683
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
595-33-5
Standard-SMILES
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
Summenformel
C24H32O4
Durchschnittliche Molmasse
384,5 g/mol
Monoisotopische Masse
384,2300595

Überblick

Megestrol Acetate can cause cancer and developmental toxicity according to state or federal government labeling requirements.

Namen und Bezeichner

Bevorzugter Name
Megestrol Acetate
IUPAC
[(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
Lokaler Name
17-Hydroxy-6-methylpregna-4,6-dien-3,20-dion-17-acetat
Englischer Name
Megestrol acetate
Summenformel
C24H32O4
Molmasse
384.51

Namen und Synonyme

MEGESTROL ACETATE595-33-5Megestryl acetateMegaceNiagestinMegeronOvabanOvaridMegace ESMegestatBDH 1298Maygace
Weitere Namen anzeigen
S4MGANia17alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dioneMEGESTROL ACETATE-D3bdh1298sc103636-MethleneProgesterone AcetateMEGESTROLACETATE,MILLEDPOWDER,USP17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
PallaceMagestinVolidanSC 10363NSC-71423MegestilMegesterol acetateSC-10363

Datenbank-Bezeichner

CAS
595-33-5
PubChem CID
11683
DTXSID
DTXSID9040683
ChEMBL
CHEMBL1201139

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,1
Polarare Oberfläche (TPSA)
60,4 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
3
Schwere Atome
28
Formalladung
0
Komplexität
820

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 2 Einträge

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point218.0-220.0 °C
Collision Cross Section · 2 Einträge

198.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID9040683]

180.1 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H302 (15.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P319, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 125 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Hazard Traits - Carcinogenicity; Developmental Toxicity

Megestrol acetate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (15.2%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Megestrol acetate

Ambiguous-DILI-concern

1

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Megestrol acetate

0.9

3.9

For treatment of endometrial carcinoma, the dosage is 40 to 320 mg/day in divided doses.

Chemie und Industrie

Pharmakologische Informationen

Pharmacodynamics · 1 Eintrag

Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. These effects include induction of secretory changes in the endometrium, increase in basal body temperature, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. Mestrogel has slight glucocorticoid activity and very slight mineralocorticoid activity. This drug has no estrogenic, androgenic, or anabolic activity. The precise mechanism of megestrol’s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.

Mechanism of Action · 1 Eintrag

The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes.

Biological Half-Life34 hours
Metabolism/Metabolites · 1 Eintrag

Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.

FDA Pharmacological Classification · 2 Einträge

MEGESTROL ACETATE

Progesterone Congeners [CS]; Progestin [EPC]

MeSH Pharmacological Classification · 2 Einträge

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 325279
HRID 325279als Produkt
Reaktionsgleichung von HRID 894643
HRID 894643als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEBI
CHEBI:6723
UNII
TJ2M0FR8ES
EC Number
209-864-5
Nikkaji
J6.777F

Physikochemische Eigenschaften

Schmelzpunkt
214 °C · 214°C
Siedepunkt
431.17 °C · 431.17°C (rough estimate)
Dichte
1.0474 · 1.0474 (rough estimate)
Brechungsindex
11 ° · 11 ° (C=2, CHCl3)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Practically insoluble in water, soluble in acetone, sparingly soluble in alcohol.
Aggregatzustand
Solid
Farbe
White
Merck
14 · 14,5805
BRN
1917291 · 1917291
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
SMILES
C1(=O)C=C2[C@](C)(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)CC3)C=C2C
CAS Datenbank
595 · 595-33-5(CAS DataBase Reference)
NIST chemische Informationen
Megestrol acetate(595-33-5)
EPA chemische Informationen
Megestrol acetate (595-33-5)

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 40 mg/day, Lowest Therapeutic Dose (LTD): 0.5 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

4-Oct-18

Sicherheitsdaten

wgk
3
hs_code
29372390
RTECS-Nr.
TU4075000
risk_code
40-48
Toxizität
LD50 intravenous in mouse: 56mg/kg
hazard_code
Xn
safety_code
22-24/25

Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.

Absorption, Distribution and Excretion · 2 Einträge

Variable, but well absorbed orally.

The major route of drug elimination in humans is urine. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.

Verwendung und Herstellung

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Anwendungen · 2 Einträge

BeschreibungMegestrol Acetate is the acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. It is frequently used in the treatment of patients with metastatic breast cancer. It is generally well tolerated, except that it may cause undesirable weight gain. Subsequently, it was shown that megestrol acetate produced weight gain in a variety of cachectic cancer patients. Significant reduction inserum levels of IL-1a and b,IL-2,IL-6, and TNF-o were observed in cancer patientstreated with megestrol acetate which may bear on the mechanism of improved appetite and body weight gain.It has also been postulated that the effect is, at least in part,mediated by NPY,a potent central appetite stimulant.

VerwendenMegestrol acetate (Megace), a semi-synthetic progestational steroid, is the most effective known appetite stimulant at present. Previously used in patients with cancer and acquired immunodeficiency syndrome, only a few studies have considered the applicability of this drug in malnourished older persons. Megestrol acetate is useful if profound anorexia is the main manifestation of cachexia and if expected survival is weeks to months. Megace has been shown to significantly increase appetite, but not survival. In patients with a shorter predicted survival, a brief course of corticosteroids may be useful to stimulate appetite and have positive effects on nausea, pain, and asthenia.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

HydroxyprogesteronKaliumtetrahydroborat16α,17-Epoxypregn-4-en-3,20-dionp-BenzochinonAluminiumtri-tert-butanolat

Nachgelagerte Produkte

17-Hydroxy-6-methylpregn-4-ene-3,20-dione 17-acetate